Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The therapeutic mechanism of metformin action remains incompletely understood. Whether metformin inhibits glucagon-stimulated endogenous glucose production (EGP), as in preclinical studies, is unclear in humans. To test this hypothesis, we studied nine prediabetic individuals using a randomized, placebo-controlled, double-blinded, crossover study design. Metformin increased glucose tolerance, insulin sensitivity, and plasma glucagon. Metformin did not alter average basal EGP, although individual variability in EGP correlated with plasma glucagon. Metformin increased basal EGP in individuals with severe hyperglucagonemia (>150 pg/ml). Decreased fasting glucose after metformin treatment appears to increase glucagon to stimulate EGP and prevent further declines in glucose. Similarly, intravenous glucagon infusion elevated plasma glucagon (>150 pg/ml) and stimulated a greater increase in EGP during metformin therapy. Metformin also counteracted the protein-catabolic effect of glucagon. Collectively, these data indicate that metformin does not inhibit glucagon-stimulated EGP, but hyperglucagonemia may decrease the ability of the metformin to lower EGP in prediabetic individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 3×
“Previous findings in a pre-clinical model indicated that metformin lowers basal EGP by diminishing the use of gluconeogenic substrates (Madiraju et al., 2014).”
Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 2×
“Therefore, several lines of evidence suggest thatmetformin lowers EGPby independent or perhaps combined mechanisms that change rate-limiting gluconeogenic enzyme levels (He et al., 2009; Foretz et al., 2010), decrease glucagon action (Miller et al.”
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148 · cited 3×
“Previous reports that administered metformin over a longer period have indicated that metformin lowers basal EGP in T2DM (Hundal et al., 2000; Stumvoll et al., 1995), but we found that, in prediabetic humans, the decline in EGP was prevented by a compensatory increase in glucagon levels.”
Interplay between lipids and branched-chain amino acids in development of insulin resistance
Newgard, C. B. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.024 · Cited by 1,080 · cited 1×
“We also examined the effect of metformin on whole-body protein metabolism because amino acids and their metabolites may affect insulin sensitivity (Everett et al., 1981; Nair et al., 1992; Newgard, 2012) and play a key role in determining gluconeogenesis through regulating substrate availability (Felig et al.”
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 2×
“Previous reports that administered metformin over a longer period have indicated that metformin lowers basal EGP in T2DM (Hundal et al., 2000; Stumvoll et al., 1995), but we found that, in prediabetic humans, the decline in EGP was prevented by a compensatory increase in glucagon levels.”
Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2074 · Cited by 806 · cited 1×
“In T2D individuals, metformin lowers blood glucose by decreasing endogenous glucose production (EGP) (DeFronzo et al., 1991; Hundal et al., 2000; Musi et al., 2002; Stumvoll et al., 1995).”
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448 · cited 1×
“Although preclinical models have provided clues regarding how metformin may elicit its therapeutic effect, translating these mechanisms to the clinical situation has been difficult because many studies have used supra-pharmacologic dosing schemes and biguanide derivatives contraindicated for human use (He et al., 2009…”
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · cited 1×
“Studies combining metformin therapy with glucagon-like peptide 1 (GLP1) agonists or dipeptidyl peptidase 4 (DPP4) inhibitors have demonstrated a synergetic effect in achieving glycemic control (Zander et al., 2001; DeFronzo et al., 2009; Solis-Herrera et al., 2013) in T2DM, but it remains to be determined whether such…”
Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Metformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats
Duca, F. A., Côté, C. D., Rasmussen, B. A., Zadeh-Tahmasebi, M., Rutter, G. A., Filippi, B. M., & Lam, T. K. T. (2015) · Nature Medicine · doi:10.1038/nm.3787 · Cited by 402
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 2×
“It is possible that the improvement in glucose tolerance and insulin sensitivity occurred because of other mechanisms of action, such as the influence of metformin in the gut (Duca et al., 2015; Buse et al., 2016), because this study has not identified the mechanism of action by which metformin improves indices of ins…”
Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients.
Nair, K. S., Ford, G. C., Ekberg, K., Fernqvist-Forbes, E., & Wahren, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118000 · Cited by 239 · cited 2×
“These results corroborate previous reports that leucine transamination is influenced by insulin treatment and glycemic control in diabetic individuals (Halvatsiotis et al., 2002; Nair et al., 1995).”
Self-citationCobelli, C., Dalla Man, C., Toffolo, G., Basu, R., Vella, A., & Rizza, R. (2014) · Diabetes · doi:10.2337/db13-1198 · Cited by 216 · cited 1×
“Mixed Meal Tolerance Test Insulin sensitivity (SI); total, dynamic, and static b cell responsivity (F, FD, and FS); and DIs (DID and DIS) were modeled after a mixed meal (600 kcal; 30% carbohydrate, 55% fat, and 15% protein) (Cobelli et al., 2014).”
Self-citationIncreased energy expenditure in poorly controlled Type 1 (insulin-dependent) diabetic patients
Nair, K. S., Halliday, D., & Garrow, J. S. (1984) · Diabetologia · doi:10.1007/bf00253494 · Cited by 122 · cited 1×
“During placebo treatment, glucagon, as previously reported, increased resting energy expenditure (Nair et al., 1984), but the glucagon effect on resting energy expenditure was not observed during metformin treatment (Table 1).”
Self-citationHyperglucagonemia during insulin deficiency accelerates protein catabolism
Nair, K. S., Halliday, D., Matthews, D. E., & Welle, S. L. (1987) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1987.253.2.e208 · Cited by 87
Self-citationLalia, A. Z., Johnson, M. L., Jensen, M. D., Hames, K. C., Port, J. D., & Lanza, I. R. (2015) · Diabetes Care · doi:10.2337/dc14-3101 · Cited by 73
Self-citationCharlton, M. R., & Nair, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1748 · Cited by 65
Self-citation
Cited by
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
Cellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
Self-citationMetformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo
Madiraju, A. K., Qiu, Y., Perry, R. J., Rahimi, Y., Zhang, X.-M., Zhang, D., Camporez, J.-P. G., Cline, G. W., Butrico, G. M., Kemp, B. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0125-4 · Cited by 297
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Metadata
- Authors
- Konopka, A. R., Esponda, R. R., Robinson, M. M., Johnson, M. L., Carter, R. E., Schiavon, M., Cobelli, C., Wondisford, F. E., Lanza, I. R., & Nair, K. S.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 15
- Issue
- 7
- Pages
- 1394-1400
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2345837088
- Cited by
- 67
- References
- 20
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.